Results 211 to 220 of about 173,203 (312)

Nonlinear Association Between BMI and Depression Among Nonalcoholic Fatty Liver Disease: NHANES (2017-2018). [PDF]

Behav Neurol
Peng H, Zhou D, Dai Y, Chen W.
europepmc   +1 more source

Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

Hepatology, 2010
H. Tilg, A. Moschen
semanticscholar   +1 more source

Unveiling the Crucial Nexus: Mitochondrial Quality Control as a Central Driver in Metabolic Dysfunction‐Associated Steatotic Liver Disease Pathogenesis

Cell Proliferation, EarlyView.
Mitochondrial quality control (MQC) impairment plays a central role in driving the pathogenesis of metabolism‐associated steatotic liver disease (MASLD). Specifically, this is manifested as reduced mitophagy; increased mitochondrial fission and decreased fusion; and impaired mitochondrial biogenesis.
Wenkai Fu, Junqi Wang, Nan Lu, Zhijiang Guo, Sang‐Bing Ong, Yong Gao, Hao Zhou, Xing Chang, Miao Meng   +8 more
wiley   +1 more source

Comparative mortality outcomes in metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease subtypes in the United States. [PDF]

PLoS One
Zhang P, Yang S, Hu R, Peng T, Yu P, Zeng Y, Ye C, Wang P, Dong X, Che Z.   +9 more
europepmc   +1 more source

The Portal Venous Pulsatility Index and Main Portal Vein Diameter as Surrogate Markers for Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Metabolic-Dysfunction-Associated Steatotic Liver Disease [PDF]

Jaejun Lee, Seung Myeon Choi, Seong-Hyun Cho, Hyun Yang, Pil Soo Sung, Si Hyun Bae   +5 more
openalex   +1 more source

Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad

European Journal of Clinical Investigation, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a major global cause of liver disease, driven by obesity and insulin resistance (IR). IR promotes hepatic lipid accumulation, inflammation and mitochondrial dysfunction, accelerating MASLD progression to fibrosis, cirrhosis and hepatocellular carcinoma (HCC).
Alfredo Caturano, Enes Erul, Roberto Nilo, Davide Nilo, Vincenzo Russo, Luca Rinaldi, Carlo Acierno, Erman Akkus, Katerina Koudelkova, Federica Cerini, Alessandro Rizzo, Ferdinando Carlo Sasso, Leonilde Bonfrate, Antonio Giordano, Hatime Arzu Yaşar, Caterina Conte   +15 more
wiley   +1 more source

Causal Relationship Between Genetically Determined Free Fatty Acids and Nonalcoholic Fatty Liver Disease: A Mendelian Randomization Study. [PDF]

Int J Endocrinol
Li K, Liang Y, Zhang X, Hu P, Hu M.
europepmc   +1 more source

TSC22D1 is a newly identified inhibitor of insulin secretion in pancreatic beta cells

The FEBS Journal, EarlyView.
TSC22D1 acts downstream of glucose signaling and negatively regulates insulin secretion in pancreatic beta cells. Mechanistically, TSC22D1 interacts with FoxO1. Elevated glucose levels enhance the TSC22D1–FoxO1 interaction indirectly by increasing the protein abundance of TSC22D1. Importantly, TSC22D1 and FoxO1 not only physically associate but also co‐
Sümbül Yıldırım, Amit Mhamane, Svenja Lösch, Annika Wieder, Ezgi Ermis, Ann‐Christine König, Sevgican Yilmaz, Stefanie M. Hauck, Fatih Kocabas, Julia Szendroedi, Stephan Herzig, Bilgen Ekim   +11 more
wiley   +1 more source

Managing Nonalcoholic Fatty Liver Disease Through Structured Lifestyle Modification Interventions. [PDF]

Am J Lifestyle Med
Thomas A, Thomas A.
europepmc   +1 more source

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.

Diabetes, 2001
G. Marchesini, M. Brizi, G. Bianchi, S. Tomassetti, E. Bugianesi, M. Lenzi, A. McCullough, S. Natale, G. Forlani, N. Melchionda   +9 more
semanticscholar   +1 more source